Morgan Stanley’s Freeline Therapeutics Holdings plc American Depositary Shares FRLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-85,514
| Closed | -$545K | – | 8078 |
|
|
2023
Q4 | $545K | Buy |
85,514
+43,080
| +102% | +$231K | ﹤0.01% | 5586 |
|
|
2023
Q3 | $182K | Buy |
42,434
+7,572
| +22% | +$29.9K | ﹤0.01% | 5628 |
|
|
2023
Q2 | $89.9K | Buy |
34,862
+22,228
| +176% | +$87.7K | ﹤0.01% | 6000 |
|
|
2023
Q1 | $86.2K | Sell |
12,634
-126
| -1% | -$978 | ﹤0.01% | 6073 |
|
|
2022
Q4 | $90.9K | Buy |
12,760
+1,217
| +11% | +$11.6K | ﹤0.01% | 6017 |
|
|
2022
Q3 | $121K | Sell |
11,543
-1,320
| -10% | -$17.2K | ﹤0.01% | 5986 |
|
|
2022
Q2 | $168K | Buy |
12,863
+548
| +4% | +$7.05K | ﹤0.01% | 5982 |
|
|
2022
Q1 | $207K | Buy |
12,315
+5,213
| +73% | +$96.7K | ﹤0.01% | 5908 |
|
|
2021
Q4 | $211K | Buy |
7,102
+4,346
| +158% | +$178K | ﹤0.01% | 6033 |
|
|
2021
Q3 | $141K | Buy |
2,756
+514
| +23% | +$36.6K | ﹤0.01% | 6186 |
|
|
2021
Q2 | $274K | Buy |
2,242
+754
| +51% | +$117K | ﹤0.01% | 5857 |
|
|
2021
Q1 | $275K | Sell |
1,488
-303
| -17% | -$71.8K | ﹤0.01% | 5477 |
|
|
2020
Q4 | $490K | Buy |
1,791
+911
| +104% | +$229K | ﹤0.01% | 5092 |
|
|
2020
Q3 | $206K | Buy |
+880
| New | +$221K | ﹤0.01% | 5103 |
|
Morgan Stanley's FRLN Position: Q1 2024 in Review
Morgan Stanley sold out of Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) in Q1 2024, closing a stake of 85,514 shares — an estimated $545K sold.
Morgan Stanley first reported a position in FRLN in Q3 2020 and held it in 14 quarters. The position peaked at $545K in Q4 2023. 0 funds tracked by Wall St. Rank hold FRLN as of Q1 2024.
- Morgan Stanley reported no remaining Freeline Therapeutics Holdings plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
- Morgan Stanley sold 85,514 Freeline Therapeutics Holdings plc American Depositary Shares shares in Q1 2024, an estimated $545K.
- Morgan Stanley first reported a position in Freeline Therapeutics Holdings plc American Depositary Shares in Q3 2020 and held it in 14 quarters.
- Morgan Stanley's Freeline Therapeutics Holdings plc American Depositary Shares position peaked at $545K in Q4 2023.
- 0 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings plc American Depositary Shares as of Q1 2024.
Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.